Literature DB >> 10470130

Topoisomerase II alpha expression in esophageal squamous cell carcinoma.

Y Ohashi1, H Sasano, H Yamaki, S Shizawa, A Kikuchi, R Shineha, T Akaishi, S Satomi, H Nagura.   

Abstract

BACKGROUND: DNA topoisomerase II alpha (topo II alpha) is associated with active cell proliferation of mammalian cells. Topo II alpha overexpression has been reported in a number of human malignancies and is considered to be related to their biological behaviors.
MATERIALS AND METHODS: We examined the expression of topo II alpha immunohistochemically in 136 cases of human esophageal squamous cell carcinoma, 10 foci of squamous dysplasia and 10 non-pathologic squamous epithelium. We calculated the labeling index (LI) or the percentage of immunopositive cells for Topo II alpha and Ki67, and Topo II alpha LI/Ki67 LI (T/K ratio). These findings were then correlated with clinicopathological features of the patients including their clinical outcome.
RESULTS: Both topo II alpha and Ki67 immunoreactivity were detected in the nuclei. A significant positive correlation was obtained between Topo II alpha and Ki67 LIs in all the specimens examined. Topo II alpha LI and T/K ratio were 24.5 +/- 8.0% and 1.04 +/- 0.64 for carcinoma, 19.1 +/- 15.2% and 0.68 +/- 0.29 for dysplasia and 14.0 +/- 14.1% and 0.55 +/- 0.17 for non-pathologic epithelium, respectively. Topo II alpha LI and T/K ratio in carcinoma cases were significantly higher than those of normal epithelium. Topo II alpha LI alone did not correlate with any of clinicopathological parameters examined but among carcinoma cases, cases with lymph nodes metastasis or higher histological stages had significantly higher T/K ratio than those without lymph node metastasis or lower histological stages. In addition, carcinoma cases with T/K ratio of greater than 0.8 demonstrated significantly worse prognosis than those with T/K ratio of smaller than 0.8.
CONCLUSIONS: The relative overexpression of topo II alpha as compared with Ki67, i.e., increased T/K ratio was detected in esophageal squamous cell carcinoma and is considered to represent a dysregulation or qualitative alteration in topo II alpha, possibly associated with malignances, as reported in other human cancers. In addition, topo II alpha overexpression may also be correlated with the aggressive biological behavior of the patients with esophageal squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10470130

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy.

Authors:  Yousaf Ali; Shafida Abd Hamid
Journal:  Tumour Biol       Date:  2015-10-20

2.  Predictive value of topoisomerase II alpha immunostaining in urothelial bladder carcinoma.

Authors:  L Nakopoulou; A Zervas; A C Lazaris; C Constantinides; C Stravodimos; P Davaris; C Dimopoulos
Journal:  J Clin Pathol       Date:  2001-04       Impact factor: 3.411

3.  Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas.

Authors:  Xiao-Ling Xu; Wei-Hui Zheng; Zhi-Xuan Fu; Zhu-Peng Li; Hua-Xia Xie; Xian-Xing Li; Lie-Hao Jiang; Yin Wang; Shuang-Mei Zhu; Wei-Min Mao
Journal:  Med Oncol       Date:  2014-11-29       Impact factor: 3.064

Review 4.  Clinical applications of urinary cell-free DNA in cancer: current insights and promising future.

Authors:  Tian Lu; Jinming Li
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

5.  TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.

Authors:  Meenu Jain; Lisa Zhang; Mei He; Ya-Qin Zhang; Min Shen; Electron Kebebew
Journal:  Endocr Relat Cancer       Date:  2013-05-21       Impact factor: 5.678

6.  Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.

Authors:  Tadayuki Akagi; Tetsuo Ito; Motohiro Kato; Zhe Jin; Yulan Cheng; Takatsugu Kan; Go Yamamoto; Alexandru Olaru; Norihiko Kawamata; Jessica Boult; Harmik J Soukiasian; Carl W Miller; Seishi Ogawa; Stephen J Meltzer; H Phillip Koeffler
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

7.  Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer.

Authors:  Ye-Hwan Kim; Chunri Yan; Il-Seok Lee; Xuan-Mei Piao; Young Joon Byun; Pildu Jeong; Won Tae Kim; Seok-Joong Yun; Wun-Jae Kim
Journal:  Investig Clin Urol       Date:  2016-03-11

8.  The significance of Epstein Barr virus (EBV) & DNA topoisomerase II alpha (DNA-Topo II alpha) immunoreactivity in normal oral mucosa, oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC).

Authors:  Ali A Shamaa; Manal M Zyada; Mathias Wagner; Sally S Awad; Mohamed M Osman; Ali A Abdel Azeem
Journal:  Diagn Pathol       Date:  2008-11-20       Impact factor: 2.644

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.